Zymeworks has dosed the first patient in a Phase 1 clinical trial evaluating ZW171 for advanced ovarian cancer, NSCLC, and other mesothelin-expressing cancers.
Zymeworks Inc. has outlined its strategic priorities for 2024 and 2025, focusing on advancing its R&D pipeline, including the development of zanidatamab for HER2-positive cancers, and expanding its portfolio of antibody-drug conjugates (ADCs) and multispecific antibody therapeutics. The company expects significant milestones, including regulatory reviews and top-line data readouts from pivotal clinical trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.